Review article · 2025
Risk of Malignancies and Major Adverse Cardiovascular Events Related to JAK Inhibitors in Rheumatoid Arthritis: A Meta‐Analysis
Clinical Pharmacology & Therapeutics, 119(3), 598–607 · Published 22 December 2025 · DOI 10.1002/cpt.70146
In brief
“Risk of Malignancies and Major Adverse Cardiovascular Events Related to JAK Inhibitors in Rheumatoid Arthritis: A Meta‐Analysis” is a 2025 review article by Hongmei Duan and 6 co-authors, published in Clinical Pharmacology & Therapeutics. OpenAlex counts 10 citations as of 17 November 2026, which puts it in the top 2% of works published in 2025 by citations. The publisher's version is not open access, and OpenAlex records no free legal copy.
- Citations
- 10
- Most cited in
- 2026 (10)
- Field-weighted impact
- 1.16
- References
- 43
- Authors
- 7
Abstract
This meta-analysis evaluated the risk of malignancies and major adverse cardiovascular events (MACE) associated with the use of JAK inhibitors in patients with RA through a comprehensive meta-analysis of available clinical trials. A systematic search was conducted in PubMed, EMBASE, and Web of Science from inception to February 7, 2025, to identify relevant clinical trials.… Read the full abstract at the publisher.
Excerpt. This paper is not open access.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Duan, H., Jiang, C., Zhang, B., Meng, H., Zhou, W., Yan, W., & Jiang, T. (2025). Risk of Malignancies and Major Adverse Cardiovascular Events Related to JAK Inhibitors in Rheumatoid Arthritis: A Meta‐Analysis. Clinical Pharmacology & Therapeutics, 119(3), 598–607. https://doi.org/10.1002/cpt.70146
MLA 9
Duan, Hongmei, et al. “Risk of Malignancies and Major Adverse Cardiovascular Events Related to JAK Inhibitors in Rheumatoid Arthritis: A Meta‐Analysis.” Clinical Pharmacology & Therapeutics, vol. 119, no. 3, 2025, pp. 598–607. https://doi.org/10.1002/cpt.70146.
Chicago
Duan, Hongmei, Chao Jiang, Binglun Zhang, Hefan Meng, Weizheng Zhou, Wei Yan, and Tianlong Jiang. 2025. “Risk of Malignancies and Major Adverse Cardiovascular Events Related to JAK Inhibitors in Rheumatoid Arthritis: A Meta‐Analysis.” Clinical Pharmacology & Therapeutics 119 (3): 598–607. https://doi.org/10.1002/cpt.70146.
Harvard
Duan, H. et al. (2025) ‘Risk of Malignancies and Major Adverse Cardiovascular Events Related to JAK Inhibitors in Rheumatoid Arthritis: A Meta‐Analysis’, Clinical Pharmacology & Therapeutics, 119(3), pp. 598–607. doi:10.1002/cpt.70146.
IEEE
H. Duan et al., “Risk of Malignancies and Major Adverse Cardiovascular Events Related to JAK Inhibitors in Rheumatoid Arthritis: A Meta‐Analysis,” Clinical Pharmacology & Therapeutics, vol. 119, no. 3, pp. 598–607, 2025, doi: 10.1002/cpt.70146.
BibTeX
@article{duan2025risk,
title = {{Risk of Malignancies and Major Adverse Cardiovascular Events Related to JAK Inhibitors in Rheumatoid Arthritis: A Meta‐Analysis}},
author = {Duan, Hongmei and Jiang, Chao and Zhang, Binglun and Meng, Hefan and Zhou, Weizheng and Yan, Wei and Jiang, Tianlong},
journal = {Clinical Pharmacology \& Therapeutics},
year = {2025},
volume = {119},
number = {3},
pages = {598--607},
doi = {10.1002/cpt.70146},
url = {https://doi.org/10.1002/cpt.70146}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- JAK inhibitors
- rheumatoid arthritis
- cancer risk
- major adverse cardiovascular events
- lymphoma
- non-small cell lung cancer
- cutaneous squamous cell carcinoma
- thyroid cancer
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Duan, H., Jiang, C., Zhang, B., Meng, H., Zhou, W., Yan, W., & Jiang, T. (2025). Risk of Malignancies and Major Adverse Cardiovascular Events Related to JAK Inhibitors in Rheumatoid Arthritis: A Meta‐Analysis. Clinical Pharmacology & Therapeutics, 119(3), 598–607. https://doi.org/10.1002/cpt.70146
How many times has this paper been cited?
10 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.
Who wrote this paper?
Hongmei Duan, Chao Jiang, Binglun Zhang, Hefan Meng, Weizheng Zhou, Wei Yan, Tianlong Jiang.
What is the DOI of this paper?
10.1002/cpt.70146, permanently at https://doi.org/10.1002/cpt.70146. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.